![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1804312
¼¼°èÀÇ ÀýÁ¦ ±â¼ú ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ±Ô¸ð, »ê¾÷ ¿ªÇÐ, ±âȸ ºÐ¼®, ¿¹Ãø(2025-2034³â)Global Ablation Technology Market: By Type, Application, End Users, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2034 |
¼¼°è ÀýÁ¦ ±â¼ú ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ(CVD), °íÇü Á¾¾ç, ¸¸¼º ÅëÁõÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î ¿ªµ¿ÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 68¾ï 2,000¸¸ ´Þ·¯·Î, 2034³â±îÁö 167¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£¿¡ CAGR·Î 9.82%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. ƯÈ÷ ÆÞ½º Çʵå, ±ØÀú¿Â, ¸¶ÀÌÅ©·ÎÆÄ ÀýÁ¦ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüÀº ƯÈ÷ ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡¼ äÅà Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹, ÀϺ», Àεµ, Áß±¹ µîÀÇ ±¹°¡¿¡¼´Â Ä¡·á ºÐ¾ß Àü¹Ý¿¡ °ÉÄ£ ÀýÁ¦¼úÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¿¡¼¸¸ 2024³â ½ÉÀå ÀýÁ¦¼ú °Ç¼ö´Â 48¸¸ °ÇÀÌ ³Ñ°í, Á¾¾ç ÀýÁ¦¼úÀº Àü ¼¼°è¿¡¼ 85¸¸ °ÇÀÌ ³ÑÀ¸¸ç, °£¾Ï ÀýÁ¦¼úÀÌ 3ºÐÀÇ 1 ÀÌ»óÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
FDA ½ÂÀÎ ÆÞ½º Çʵå ÀýÁ¦(PFA) ½Ã½ºÅÛ, AI Áö¿ø ¸ÅÇÎ Ç÷§Æû, ÀÏȸ¿ë ÇÁ·Îºê µîÀÇ Çõ½ÅÀÌ ÀÓ»óÀ» º¯È½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¿ë È¿À²¼º°ú È¿À²¼º ¶§¹®¿¡ ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)°¡ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖÀ¸¸ç, ¹Ì±¹¿¡¼´Â ÇöÀç ÀýÁ¦ ¼ö¼úÀÇ 55% ÀÌ»óÀÌ ±âÁ¸ º´¿ø ¹Û¿¡¼ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡µéÀº ÀÇ·á ÀÎÇÁ¶ó °³¼±, Á¤ºÎ ÁÖµµÀÇ ³ë·Â, Àü±â»ý¸®ÇÐ ¹× Á¾¾çÇÐ Àü¹®°¡ ¾ç¼º Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
ÀÏ·ÃÀÇ ¹ßÀüÀº ÀýÁ¦ ±â¼úÀÇ ¸ð¸àÅÒÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ½Äµµ ¼Õ»óÀÇ À§Çè°ú ½Ã¼ú ½Ã°£À» ÁÙ¿©ÁÖ´Â ÆÞ½º Çʵå ÀýÁ¦¼úÀº ºü¸£°Ô ¹Þ¾Æµé¿©Áö°í ÀÖÀ¸¸ç, ÀÌ¹Ì ¹Ì±¹ ½ÉÀå ÀýÁ¦¼ú »ç·ÊÀÇ 25%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. MedtronicÀÇ Affera Ç÷§Æû°ú Johnson & JohnsonÀÇ ¼¶À¯Áõ ¸ÅÇÎ Åø(Verily¿Í Á¦ÈÞ)°ú °°Àº AI °¡ÀÌµå ½Ã½ºÅÛÀº ½Ã¼úÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÀýÁ¦¼úÀÇ ¹Ýº¹·üÀ» ³·Ãß°í ÀÖ½À´Ï´Ù. °£Á¾¾ç¿¡ ´ëÇÑ ¿Ü·¡ ÀýÁ¦¼úÀº ÇöÀç 90% À̻󿡼 ´çÀÏ Åð¿øÀÌ °¡´ÉÇØ ÀÇ·á½Ã½ºÅÛÀÇ È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÇÑÆí, Àεµ¿Í °°Àº ±¹°¡¿¡¼´Â ¼ö¼ú ÈÄ ÇÕº´ÁõÀÌ Å©°Ô °¨¼ÒÇÏ¸é¼ Àü¸³¼± Àú¿Â ÀýÁ¦¼úÀÌ Àü³â ´ëºñ 22% ¼ºÀåÇß½À´Ï´Ù.
¾ç»ç´Â ÇÏÀ̺긮µå ÀýÁ¦ ½Ã½ºÅÛ ¹× ¿Ü·¡ ȯ°æ¿¡ ÃÖÀûÈµÈ ¸ðµâÇü ŰƮ¸¦ °³¹ßÇϱâ À§ÇØ ÆÄÆ®³Ê½ÊÀ» ¸Î°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¸ÞµåÆ®·Î´Ð°ú GEÇコÄɾî´Â ½Ç½Ã°£ MRI °¡ÀÌ´ø½º¸¦ ÀýÁ¦ Ç÷§Æû¿¡ ÅëÇÕÇÏ¿© Á¾¾ç Àý´ÜÀÇ °¡½Ã¼ºÀ» °³¼±Çϱâ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È°µ¿Àº ¹Ì±¹ÀÇ ¸ÞµðÄɾî(Medicare) Àû¿ë ¹üÀ§ È®´ë¿Í °°Àº »óȯ Á¤Ã¥ÀÇ ÁøÀü, Àåºñ ºñ¿ë Àý°¨°ú ¼ºñ½º ¼Ò¿Ü Áö¿ªÀÇ Á¢±Ù¼º È®´ë¸¦ ¸ñÇ¥·Î ÇÏ´Â ºê¶óÁúÀÇ ¹Î°ü ÆÄÆ®³Ê½Ê¿¡ ÀÇÇØ ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎ
1. ´ë»ó ÁúȯÀÇ À¯º´·ü Áõ°¡: Àü ¼¼°è¿¡¼ 2,600¸¸ ¸í ÀÌ»óÀÌ ¾Î°í ÀÖ´Â ½É¹æ¼¼µ¿(AFib)°ú ±¹¼Ò¾ÏÀÇ À¯º´·ü Áõ°¡°¡ ÀýÁ¦¼ú Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.
2. ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£: ÀýÁ¦¼úÀº ȸº¹±â°£ ´ÜÃà, ¿Ü»ó °¨¼Ò, ÀÔ¿ø ºñ¿ë Àý°¨ µîÀÇ ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, º¸±ÞÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.
3. ±â¼ú Çõ½Å : ÈÞ´ë¿ë AI ÅëÇÕ ½Ã½ºÅÛ ¹× ÀÏȸ¿ë ÇÁ·ÎºêÀÇ µîÀåÀº ƯÈ÷ ¿Ü·¡¿¡¼ Ä¡·á ¼º°ú¿Í ȯÀÚ ¾ÈÀüÀ» Çâ»ó½Ãŵ´Ï´Ù.
4. Á¤ºÎ Áö¿ø ¹× »óȯ Á¤Ã¥: ¹Ì±¹ CMSÀÇ »óȯ °»½Å ¹× ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·á º¸Á¶±Ý µîÀÇ Á¤Ã¥ÀÌ À¯¸®ÇÑ ½ÃÀå ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.
»õ·Î¿î ±â¼ú µ¿Çâ
¼¼°èÀÇ ÀýÁ¦ ±â¼ú ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, °¢ ºÎ¹® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ½ÃÀå ¿ªÇаú µ¿Çâ, ±â¾÷ °³¿ä µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
The global ablation technology market is undergoing dynamic expansion, underpinned by the rising incidence of cardiovascular diseases (CVDs), solid tumors, and chronic pain conditions. Valued at US$ 6.82 billion in 2024, the market is expected to attain US$ 16.74 billion by 2034, growing at a CAGR of 9.82% over the forecast period. Technological evolution, especially in pulsed-field, cryo, and microwave ablation systems, is driving increased adoption, particularly in minimally invasive procedures. Countries like the U.S., Japan, India, and China are witnessing a significant surge in ablation procedures across therapeutic areas. For example, cardiac ablation volumes in the U.S. alone accounted for over 480,000 procedures in 2024, while tumor ablation exceeded 850,000 globally, with liver cancer ablation accounting for more than one-third of cases.
Innovations such as FDA-cleared pulsed-field ablation (PFA) systems, AI-enabled mapping platforms, and single-use probes are reshaping clinical practices. Additionally, outpatient and ambulatory surgical centers are increasingly preferred due to their cost-effectiveness and efficiency, with over 55% of ablation procedures in the U.S. now conducted outside traditional hospital settings. Simultaneously, Asia-Pacific countries are experiencing rapid expansion due to improving healthcare infrastructure, government-led initiatives, and increasing training for specialists in electrophysiology and oncology.
A series of advancements are reinforcing the momentum in the ablation technology landscape. Pulsed-field ablation, which reduces esophageal injury risks and procedural time, is rapidly gaining acceptance, already comprising 25% of U.S. cardiac ablation cases. AI-guided systems, such as Medtronic's Affera platform and Johnson & Johnson's fibrosis mapping tool (in partnership with Verily), are enhancing procedural accuracy and reducing repeat ablation rates. Outpatient ablation for liver tumors now facilitates same-day discharge in over 90% of cases, bolstering health system efficiency. Meanwhile, countries like India have witnessed a 22% year-on-year growth in prostate cryoablation, attributed to a substantial reduction in post-operative complications.
Companies are forming partnerships to develop hybrid ablation systems and modular kits optimized for ambulatory environments. Medtronic and GE Healthcare, for example, have collaborated to integrate real-time MRI guidance with ablation platforms, improving tumor margin visualization. These efforts are further supported by evolving reimbursement policies, such as Medicare's expanded coverage in the U.S., and public-private partnerships in Brazil aimed at reducing equipment costs and expanding access in underserved regions.
Core Growth Drivers
1. Rising Incidence of Target Conditions: Increasing prevalence of atrial fibrillation (AFib), which affects over 26 million people globally, and localized cancers is significantly contributing to the demand for ablation therapies.
2. Preference for Minimally Invasive Procedures: Ablation offers shorter recovery periods, less trauma, and reduced hospitalization costs, supporting widespread adoption.
3. Technological Innovations: The emergence of portable, AI-integrated systems and disposable probes enhances procedural outcomes and patient safety, especially in outpatient settings.
4. Government Support and Reimbursement Policies: Policies like the U.S. CMS's reimbursement updates and Asia-Pacific healthcare subsidies are creating favorable market environments.
Emerging Technology Trends
Barriers to Optimization
Market Segment Analysis
By Type:
Radiofrequency ablation leads the market, commanding 37% of total revenue in 2024. Its widespread use in oncology and pain management is attributed to high precision, cost-effectiveness, and robust clinical outcomes, such as an 89% 5-year survival rate in early-stage liver cancer.
Other types include:
By Application:
Cardiovascular treatments dominate, contributing 43% of overall market share in 2024. The strong growth trajectory is fueled by guideline-recommended adoption of ablation as a first-line therapy for AFib, rising prevalence of arrhythmias, and favorable reimbursement policies.
Other key applications:
By End Users:
Hospitals remain the primary end users, accounting for 66.35% of total utilization in 2024 due to their capacity to handle complex, multi-disciplinary cases, integrated diagnostic setups, and access to robotic systems and hybrid ORs.
Other end users include:
Geographic Insights
North America
Holding 48.3% of the global market share, North America is driven by high chronic disease burden, strong reimbursement frameworks, and rapid adoption of next-gen ablation platforms. Over 92% of regional revenue is concentrated in the U.S.
Europe
Europe represents 28% of the market, supported by aging populations and increasing outpatient procedure volumes. Germany and France are key contributors, though reimbursement inconsistencies across the continent pose challenges.
Asia Pacific
The fastest-growing region at a 13.2% CAGR, fueled by expanding CVD and cancer burdens, supportive government schemes, and emerging local manufacturers like Perfint Healthcare (India) and MicroPort (China).
Middle East & Africa
Adoption is rising, particularly in Gulf nations and South Africa, due to increasing private sector participation and initiatives to train specialists. However, cost barriers persist in low-income regions.
South America
Countries like Brazil and Argentina are increasing their investment in ablation infrastructure through PPPs and health system modernization programs, aiming to reduce dependency on imports and increase domestic access.
By Region